AU · rank #16 · 2026-07-22
ABVX
PARIS · EUR · $11.74B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.493 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.13 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $138.56 | +17.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +14.97% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +100.0% |
| 52w high | $139.00 |
| Market cap (USD) | $11.74B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Abivax is a clinical-stage biotech developing obefazimod, an oral once-daily small molecule in Phase 3 for ulcerative colitis with no approved products and minimal revenue.
Rationale
The analyst_upside_pct of ~18%, 100% revision agreement, a strong recent earnings surprise of 28%, and positive 44-week Phase 3 maintenance data all reinforce that analysts are converging upward on a de-risked late-stage catalyst, which is precisely the setup this strategy targets.
Material risks
- 1With only 4 analysts covering and analyst_target_dispersion_pct of ~79%, the consensus is thin and volatile — a single negative FDA interaction or NDA delay could collapse the price target cluster that drives the upside signal.
- 2The 60-day EPS revision of -$2.99 signals meaningful near-term estimate cuts beneath the surface, and the company burns ~€48M per quarter, meaning the $920M raise buys time but does not eliminate binary regulatory risk before any commercial revenue.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.